IMPROVEMENT OF LIVER STIFFNESS VALUES MEASURED BY TRANSITION ELASTOGRAPHY AFTER CHRONIC HEPATITIS C TREATMENT WITH DIRECT ACTION ANTIVIRALS AND EVOLUTIVE CORRELATION OF THROMBOCYTOPENIA AND PRESENCE OF ESOPHAGEAL VARICES

Author(s):  
Miguel Perez Ferrer
2019 ◽  
Vol 57 (2) ◽  
pp. 85-98
Author(s):  
Romeo-Gabriel Mihăilă

Abstract Introduction. The severity of liver fibrosis can be assessed noninvasively today by liver stiffness measurements. Vibration-controlled transient elastography, shear wave elastography or magnetic resonance elastography are techniques increasingly used for this purpose. Methods. This article presents the recent advances in the use of new techniques for liver fibrosis assessment in chronic hepatitis C: the correlation between liver stiffness values and liver fibrosis estimated by liver biopsies, the prognosis role of liver stiffness values, their usefulness in monitoring the treatment response, in assessing the severity of portal hypertension and in estimating the presence of esophageal varices. Scientific articles from January 2017 to January 2018 were searched in PubMed and PubMed Central databases, using the terms “liver stiffness” and “hepatitis C”. Results. The median liver stiffness values measured with different techniques are not identical, so that FibroScan thresholds cannot be used on any other elastographic machine. The higher the liver’s stiffness measurement, the higher the liver-related events in patients with chronic hepatitis C. A liver stiffness measurement over 17 kPa could be an independent predictor for the presence of esophageal varices as well as a spleen with a longitudinal span ≥ 15 cm for patients with a value of liver stiffness < 17 kPa. A progressive and persistent decrease in liver stiffness is dependent on sustained virological response achievement. The lack of liver stiffness decrease has been associated with relapsers and a low value of liver stiffness at baseline. Conclusion. Liver stiffness provides clues about the severity and evolution of liver disease.


2018 ◽  
Vol 34 (5) ◽  
pp. 921-928 ◽  
Author(s):  
Ryo Nakagomi ◽  
Ryosuke Tateishi ◽  
Ryota Masuzaki ◽  
Yoko Soroida ◽  
Tomomi Iwai ◽  
...  

Medicine ◽  
2017 ◽  
Vol 96 (46) ◽  
pp. e8621 ◽  
Author(s):  
Mohammed Tag-Adeen ◽  
Mohamed Alsenbesy ◽  
Ali Abdelrahman Ghweil ◽  
M. Ali Hussein Abd Elrazek ◽  
Elsayed A. Elgohary ◽  
...  

2016 ◽  
Vol 46 (9) ◽  
pp. 884-889 ◽  
Author(s):  
Soichiro Shibata ◽  
Takeji Umemura ◽  
Tomoo Yamazaki ◽  
Naoyuki Fujimori ◽  
Yuki Ichikawa ◽  
...  

2015 ◽  
Vol 53 (08) ◽  
Author(s):  
P Buggisch ◽  
J Petersen ◽  
K Wursthorn ◽  
A Gauthier ◽  
P Atanasov

Medicina ◽  
2021 ◽  
Vol 57 (3) ◽  
pp. 210
Author(s):  
Martynas Ridziauskas ◽  
Birutė Zablockienė ◽  
Ligita Jančorienė ◽  
Artūras Samuilis ◽  
Rolandas Zablockis ◽  
...  

Background and Objectives: Chronic hepatitis C virus infection affects about 71 million people worldwide. It is one of the most common chronic liver conditions associated with an increased risk of developing liver cirrhosis and cancer. The aim of this study was to evaluate changes in liver fibrosis and the risk of developing hepatocellular carcinoma after direct-acting antiviral drug therapy, and to assess factors, linked with these outcomes. Materials and Methods: 70 chronic hepatitis C patients were evaluated for factors linked to increased risk of de novo liver cancer and ≥ 20% decrease of ultrasound transient elastography values 12 weeks after the end of treatment. Results: The primary outcome was an improvement of liver stiffness at the end of treatment (p = 0.004), except for patients with diabetes mellitus type 2 (p = 0.49). Logistic regression analysis revealed factors associated with ≥ 20% decrease of liver stiffness values: lower degree of steatosis in liver tissue biopsy (p = 0.053); no history of interferon-based therapy (p = 0.045); elevated liver enzymes (p = 0.023–0.036); higher baseline liver stiffness value (p = 0.045) and absence of splenomegaly (p = 0.035). Hepatocellular carcinoma developed in 4 (5.7%) patients, all with high alpha-fetoprotein values (p = 0.0043) and hypoechoic liver mass (p = 0.0001), three of these patients had diabetes mellitus type 2. Conclusions: Liver stiffness decrease was significant as early as 12 weeks after the end of treatment. Patients with diabetes and advanced liver disease are at higher risk of developing non-regressive fibrosis and hepatocellular carcinoma even after successful treatment.


2016 ◽  
Vol 4 ◽  
pp. 133-137
Author(s):  
Anna Piekarska ◽  
Ewa Koślińska-Berkan ◽  
Kamila Wójcik ◽  
Anna Skubała ◽  
Maciej Jabłkowski ◽  
...  

2018 ◽  
Vol 2 (9) ◽  
pp. 1111-1122 ◽  
Author(s):  
Wataru Ando ◽  
Hiroaki Yokomori ◽  
Fumihiko Kaneko ◽  
Mana Kaneko ◽  
Koji Igarashi ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document